Evidence map›Paper›PMID 41878020›Full record

ReviewClinical epidemiology2026

An Introduction to Competing Risks in Epidemiology.

Henrik Toft Sørensen, Erzsébet Horváth-Puhó, Janet L Peacock

Abstract readReview
In one paragraph

Review in Clinical epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Tyrosine kinase inhibitor use and risk of neurodegenerative disease: A Swedish population-based cohort study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Henrik Toft SørensenDepartment of Clinical Epidemiology, Center for Population Medicine, Aarhus University Hospital and Aarhus University, Aarhus, Denmark.ORCID 0000-0003-4299-7040
Erzsébet Horváth-PuhóDepartment of Clinical Epidemiology, Center for Population Medicine, Aarhus University Hospital and Aarhus University, Aarhus, Denmark.ORCID 0000-0002-3594-2212
Janet L PeacockDepartment of Clinical Epidemiology, Center for Population Medicine, Aarhus University Hospital and Aarhus University, Aarhus, Denmark.ORCID 0000-0002-0310-2518

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Competing risks arise when people are at risk of multiple mutually exclusive events, such that the occurrence of one event alters the probability of others. In research, ignoring competing risks can lead to biased estimates. We outline key approaches for analyzing competing risk data, focusing on their assumptions, interpretations, and epidemiological and clinical relevance. The Aalen-Johansen estimator, a non-parametric method for estimating the cumulative incidence function, provides an alternative to the naïve Kaplan-Meier estimator when competing events are present. The cause-specific hazard model estimates the instantaneous risk of a specific event type, treating competing events as censored, and is used for etiologic research. The Fine-Gray subdistribution hazard model directly models the cumulative incidence function, thus offering a clinically interpretable measure of absolute risk. We also discuss the use of composite endpoints, which combine several event types to increase statistical power, and highlight their limitations in clinical interpretation. By comparing these methods and illustrating their applications through analyses of the association between venous thromboembolism and arterial events, this review aims to guide researchers, particularly junior researchers, in selecting appropriate strategies for valid and meaningful analysis of competing risks in clinical and epidemiological studies.

Indexed as

Aalen-Johansen estimatorcause-specific hazard modelcompeting risksepidemiologyfine-gray subdistribution hazard model

Identifiers

PMID41878020
PMCPMC13007359

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.